102 related articles for article (PubMed ID: 12718736)
1. Genetic metamorphosis of herpes simplex virus-1 into a biological therapeutic for human cancer.
Mohr I
Expert Opin Biol Ther; 2003 Feb; 3(1):113-25. PubMed ID: 12718736
[TBL] [Abstract][Full Text] [Related]
2. A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals.
Mohr I; Sternberg D; Ward S; Leib D; Mulvey M; Gluzman Y
J Virol; 2001 Jun; 75(11):5189-96. PubMed ID: 11333900
[TBL] [Abstract][Full Text] [Related]
3. B-myb promoter retargeting of herpes simplex virus gamma34.5 gene-mediated virulence toward tumor and cycling cells.
Chung RY; Saeki Y; Chiocca EA
J Virol; 1999 Sep; 73(9):7556-64. PubMed ID: 10438845
[TBL] [Abstract][Full Text] [Related]
4. Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation.
Blank SV; Rubin SC; Coukos G; Amin KM; Albelda SM; Molnar-Kimber KL
Hum Gene Ther; 2002 Mar; 13(5):627-39. PubMed ID: 11916486
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
6. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy.
Coukos G; Makrigiannakis A; Montas S; Kaiser LR; Toyozumi T; Benjamin I; Albelda SM; Rubin SC; Molnar-Kimber KL
Cancer Gene Ther; 2000 Feb; 7(2):275-83. PubMed ID: 10770637
[TBL] [Abstract][Full Text] [Related]
7. A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation.
Samoto K; Perng GC; Ehtesham M; Liu Y; Wechsler SL; Nesburn AB; Black KL; Yu JS
Cancer Gene Ther; 2001 Apr; 8(4):269-77. PubMed ID: 11393279
[TBL] [Abstract][Full Text] [Related]
8. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
Fu X; Zhang X
Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
[TBL] [Abstract][Full Text] [Related]
9. Role of Herpes Simplex Virus 1 γ34.5 in the Regulation of IRF3 Signaling.
Manivanh R; Mehrbach J; Knipe DM; Leib DA
J Virol; 2017 Dec; 91(23):. PubMed ID: 28904192
[TBL] [Abstract][Full Text] [Related]
10. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic herpes simplex virus engineering and preparation.
Agarwalla PK; Aghi MK
Methods Mol Biol; 2012; 797():1-19. PubMed ID: 21948465
[TBL] [Abstract][Full Text] [Related]
12. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.
Todo T; Martuza RL; Rabkin SD; Johnson PA
Proc Natl Acad Sci U S A; 2001 May; 98(11):6396-401. PubMed ID: 11353831
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells.
Taneja S; MacGregor J; Markus S; Ha S; Mohr I
Proc Natl Acad Sci U S A; 2001 Jul; 98(15):8804-8. PubMed ID: 11438715
[TBL] [Abstract][Full Text] [Related]
15. Herpes simplex virus 2 ICP34.5 confers neurovirulence by regulating the type I interferon response.
Davis KL; Korom M; Morrison LA
Virology; 2014 Nov; 468-470():330-339. PubMed ID: 25238641
[TBL] [Abstract][Full Text] [Related]
16. Herpes simplex virus 1 (HSV-1) for cancer treatment.
Shen Y; Nemunaitis J
Cancer Gene Ther; 2006 Nov; 13(11):975-92. PubMed ID: 16604059
[TBL] [Abstract][Full Text] [Related]
17. Effective treatment of human breast tumor in a mouse xenograft model with herpes simplex virus type 1 specifying the NV1020 genomic deletion and the gBsyn3 syncytial mutation enabling high viral replication and spread in breast cancer cells.
Israyelyan AH; Melancon JM; Lomax LG; Sehgal I; Leuschner C; Kearney MT; Chouljenko VN; Baghian A; Kousoulas KG
Hum Gene Ther; 2007 May; 18(5):457-73. PubMed ID: 17536976
[TBL] [Abstract][Full Text] [Related]
18. Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application.
Smith KD; Shao MY; Posner MC; Weichselbaum RR
Future Oncol; 2007 Oct; 3(5):545-56. PubMed ID: 17927520
[TBL] [Abstract][Full Text] [Related]
19. Viral oncolysis by herpes simplex virus and other viruses.
Kuruppu D; Tanabe KK
Cancer Biol Ther; 2005 May; 4(5):524-31. PubMed ID: 15917655
[TBL] [Abstract][Full Text] [Related]
20. HSV-1 viral oncolysis and molecular imaging with PET.
Kuruppu D; Dorfman JD; Tanabe KK
Curr Cancer Drug Targets; 2007 Mar; 7(2):175-80. PubMed ID: 17346109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
